Navigation Links
Cardium Reports on Recent Highlights and Financial Results
Date:3/14/2008

SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today reported highlights and financial results for its fiscal year ended December 31, 2007, and other important recent developments.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Highlights and Recent Developments

-- Initiation of Phase 2b MATRIX clinical trial to evaluate the safety

and efficacy of Excellarate(TM) for the potential treatment of

non-healing diabetic foot ulcers. Excellarate is a DNA-based topical

gel that is being developed to be administered once or twice to

stimulate wound healing. The MATRIX study, a randomized,

double-blind, placebo-controlled, comparator arm clinical trial is

expected to enroll approximately 210 patients at about 30 U.S. sites.

Top line safety and efficacy data from the trial is expected to be

announced in late 2008.

-- Initiation of Phase 3 AWARE trial for Generx(TM), a randomized,

placebo-controlled, double-blind clinical trial that is expected to

enroll approximately 300 women at an estimated 50 U.S. medical

centers. Generx is being evaluated as a potential treatment for

myocardial ischemia (insufficient blood flow within the heart muscle)

which gives rise to angina associated with coronary heart disease.

The U.S. Food and Drug Administration (FDA) has granted Fast Track

designation to Generx for myocardial ischemia in view of the large

unmet medical need for effective new therapies to treat coronary heart
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
3. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2007 Results
4. Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
5. Isis Reports Financial Results and Highlights for Fiscal year 2007
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
7. Omega Protein Reports 2007 Results
8. Herley Reports Second Quarter Results
9. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
10. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
11. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Dr. Myo Nwe ... Weight Loss Diet of the Future” and co-founder of the ... her book, Dr. Nwe takes a broad look at the ... hold up under scientific scrutiny. On film and in television ... emphasized mostly toward the social aspects and played for basic ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 In its ... and its Argus Claim Review division have recently ... the most common ways savings are achieved on behalf ... attributes millions of dollars in savings to Argus each ... 2013. , As explained by Tom Doney, Cypress president ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first ... study providing evidence on the impact of 100% pure ... Sufficient enough evidence already exists showing a negative link ... with the onset of tooth decay. One question that ... 100% fruit juice, meaning it is completely natural with ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... NEW YORK, March 4, 2011 Despite significant investment in ... has seen a marked decline in the number of ... at the New York Academy of Sciences on Wednesday, ... experts in clinical, translational, and basic neuroscience to address ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... chance of getting a kidney transplant than whites do, claims ... used to decide who gets which donated organs. The ... that once "waitlisted" for a needed kidney, white patients were ...
... - DNA provides the instruction manual for all life ... and bad messages are sent leading to the creation ... , Paul Doetsch, PhD, professor of radiation oncology and ... Winship Cancer Institute and Damien Brgeon, PhD, at Institut ...
... Dr. David Levin, Professor of Molecular & Cell ... Dental Medicine and Professor of Microbiology at Boston University ... mechanism for the regulation of gene expression. The study ... Paf1 Complex Blocks Sen1-Mediated Premature Transcription Termination," appears in ...
... on producing radiation inside a tumour using,boron-10 and thermal ... help of a special carrier substance (phenylalanine), after which ... react with the boron to generate high-LET radiation, which ... treatment sessions may be sufficient to destroy a tumour, ...
... Congress on Osteoporosis & Osteoarthritis - the most ... held in Valencia,s award-winning ,Palacio de Congresos, from ... to take advantage of lower registration fees. ... world,s top bone experts, Learn about key topics in ...
Cached Medicine News:Health News:White Patients Most Likely to Get Kidney Transplants: Study 2Health News:White Patients Most Likely to Get Kidney Transplants: Study 3Health News:Nature Reviews Cancer article traces possible role of damaged DNA in tumor development 2Health News:Novel mechanism for control of gene expression revealed 2Health News:BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer 2
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 12 Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: Hajime Shimizu ... ,s Brain Science Institute (Headquarters: Baltimore, Maryland , Director: John Griffin , M.D., "BSI") related to ... ... , ...
... has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , , ... ... ...
Cached Medicine Technology:Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: